Geron Jobs and Personnel

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
huntingonthebluffs
Posts: 138
Joined: Wed Feb 24, 2016 12:00 am

Geron Jobs and Personnel

Post by huntingonthebluffs » Thu Feb 21, 2019 4:53 am

It might be useful for us to keep information regarding Geron jobs and personnel in a single thread for easy reference.

For those wanting to see current opportunities or apply you can go to:
https://www.geron.com/careers/opportunities/



To Apply
Geron is always accepting applications for employment opportunities. Listed on our “Opportunities” section above you will find all of the open positions for which we are currently recruiting. To apply, please send all resumes, CVs and cover letters to jobs@geron.com.

Responding to Your Resume
HR and the hiring manager will review your experience and background and compare them to the position for which you applied. Upon review of your resume, if we determine that there is an adequate match between our needs and your qualifications, we will contact you directly to conduct a preliminary phone interview or to set up an interview at Geron. We kindly request that you do not call us regarding the status of your resume submission due to the volume of calls we regularly handle.

Note for Principal Agencies
Principal agencies should not forward resumes to Geron through jobs@geron.com email or through the contact information below. Geron will not be responsible for any fees arising from the use of resumes through these sources. Geron will only pay a fee to agencies if a formal agreement between Geron and the agency has already been established. To be considered as an approved agency, contact the Human Resources department directly.

Human Resources Department - Contact Information
Geron Corporation
Attn: Human Resources
149 Commonwealth Drive
Menlo Park, CA 94025

Fax: 650-473-8668
Email: jobs@geron.com

huntingonthebluffs
Posts: 138
Joined: Wed Feb 24, 2016 12:00 am

Re: Geron Jobs and Personnel

Post by huntingonthebluffs » Thu Feb 21, 2019 4:59 am

Thanks to Fan and hunter on YMB for supplying this info from LinkedIn:

https://www.linkedin.com/jobs/view/life ... 017283366/

Note this job request on LinkedIn is no longer accepting applications.

Life Science Contracts Attorney
Company NameGeron Corporation Company Location San Francisco Bay Area

Geron is seeking an attorney to be responsible for reviewing clinical trial agreements, and negotiating agreements in support of Geron’s clinical program. The successful candidate will have experience with a wide range of agreements, including CDAs, consulting agreements, service agreements, assignment agreements and more, and will be able to work efficiently with internal and external operational teams to obtain necessary information to bring contracts to closure. S/he will be a self-starter, capable of working independently and as part of a cross-functional team in a fast-paced environment. Candidates must be able to review and summarize agreements, as well as to assist with entering and managing agreements in Geron’s contract tracking system. This role requires close attention to detail and strong customer service, as well as strong written and verbal communication skills.

This position is a contract position, required starting Q1 2019 through Q2 2019 (may be extended if needed). It is anticipated that the position will be full-time for the duration of the project period.

Requirements: Minimum of 4 years legal experience, with at least 3 years direct experience negotiating clinical trial agreements, including budgets
- JD required
- Detail oriented
- Capable of working independently and as part of a team; a self-starter!
- Able to prioritize and respond quickly to changing needs
- Strong written and verbal skills
- Personable and able to interact positively with Geron vendors and consultants[/list]

huntingonthebluffs
Posts: 138
Joined: Wed Feb 24, 2016 12:00 am

Re: Geron Jobs and Personnel

Post by huntingonthebluffs » Thu Feb 21, 2019 7:07 pm

Current executive employees with new / additional titles and responsibilities

(1) On January 29, 2019, the Compensation Committee approved the appointment of Ms. Behrs as the Company’s Chief Business Officer. Melissa A. Kelly Behrs has been appointed Chief Business Officer and will be responsible for business development, portfolio management, alliance management, and strategic market assessment and planning.

(2) On January 29, 2019, the Compensation Committee approved the appointment of Dr. Grethlein as the Company’s Chief Operating Officer. Andrew J. Grethlein, Ph.D., has been appointed Chief Operating Officer and will be responsible for global regulatory affairs, pharmacovigilance and drug safety, manufacturing, quality, program management, human resources and information technology.

(3) On January 29, 2019, the Compensation Committee approved the appointment of Mr. Rosenfield as the Company’s Chief Legal Officer. Stephen N. Rosenfield has been appointed Chief Legal Officer and will be responsible for legal affairs, corporate compliance, intellectual property and corporate governance.


http://ir.geron.com/node/15861/html


New executives:

(1) On January 16, 2019 Israel Gutierrez, M.D., has joined the Company as Vice President, Pharmacovigilance and Drug Safety, as of January 16, 2019. Dr. Gutierrez will lead and direct the oversight of clinical drug safety risk management and compliance at Geron and will be responsible for product safety-related recommendations and decisions. Additionally, he will be responsible for ensuring compliance for all current and planned imetelstat clinical trials in accordance with domestic and international requirements for drug safety oversight and reporting from late-stage development through commercialization. As the senior pharmacovigilance expert, Dr. Gutierrez will lead and oversee pharmacovigilance signal detection and risk management activities and risk mitigation strategies, as well as represent medical safety at all meetings with regulatory authorities.

http://ir.geron.com/news-releases/news- ... rug-safety

(2) On January 30, 2019 Aleksandra Rizo, M.D., Ph.D., former clinical lead for the imetelstat program at Janssen, joins Geron as Chief Medical Officer. Aleksandra Rizo, M.D., Ph.D., was appointed Chief Medical Officer as of January 30, 2019 and will be a member of the Company’s Executive Management Committee. Dr. Rizo will be responsible for directing imetelstat’s clinical development strategy, including designing a product development plan for current and potential future indications. Functions under Dr. Rizo’s oversight include clinical science, clinical operations, data management, biostatistics, clinical pharmacology, translational research and medical affairs.

http://ir.geron.com/news-releases/news- ... ment-chief


Board of Director changes:

(1) For personal reasons, effective December 26, 2018, Hoyoung Huh, M.D., Ph.D., has resigned from the Board, including his roles as Chairman of the Board and as a member of the Nominating and Corporate Governance Committee. Dr. Huh has served as Chairman of the Board since September 2011, and as a member of the Board since May 2010. Dr. Huh’s resignation is not due to any disagreement on matters relating to the Company’s future prospects, operations, policies or practices.

(2) Effective December 27, 2018, the Board has appointed John A. Scarlett, M.D., to serve as Chairman of the Board, in addition to his role as President and Chief Executive Officer of the Company.

(3) Effective December 27, 2018, the Board has appointed Karin Eastham, who has served on Geron’s Board since 2009, to serve as Lead Independent Director for the Board. Ms. Eastham will also retain her roles as Chairperson of the Company’s Audit Committee and a member of the Compensation Committee. As Lead Independent Director, Ms. Eastham will provide active leadership on behalf of the independent directors of the Board.

http://ir.geron.com/news-releases/news- ... -structure


(4) On January 30, 2019, Daniel M. Bradbury, a Class II member of the Company’s Board, notified the Board of his decision to not stand for re-election at the Company’s upcoming 2019 Annual Meeting of Stockholders due to his new responsibilities as a chief executive officer of another public company. Mr. Bradbury’s decision not to stand for re-election was not due to any disagreement with the Company, the Board or the management of the Company on any matter relating to the Company’s operations, policies or practices. The effective date of departure for Mr. Bradbury will be May 14, 2019, the expected date of the Company’s 2019 Annual Meeting of Stockholders. Until his departure from the Board, Mr. Bradbury will continue to serve on the Audit Committee and the Nominating and Corporate Governance Committee of the Board.

http://ir.geron.com/node/15861/html

biopearl123
Posts: 180
Joined: Fri Jul 20, 2018 5:13 pm

Re: Geron Jobs and Personnel

Post by biopearl123 » Thu Feb 21, 2019 7:26 pm

Hunt, thanks for updating this information. It seems pretty clear that there is a plan in place and Geron is gearing up. I suspect by the time the next quarterly update occurs, and it should be soon, the control should be back in Geron's hands and we should get some significant details. I am sure Dr. Scarlett is tired of hearing the howls of protest from his shareholders who feel they have been kept in the dark long enough. bp

huntingonthebluffs
Posts: 138
Joined: Wed Feb 24, 2016 12:00 am

Re: Geron Jobs and Personnel

Post by huntingonthebluffs » Sun Mar 31, 2019 7:09 pm

I know biopearl has added the link in another post but I meant to keep this information in a single post string for easy access. While director appointments may not fall in the same category as employees, I believe it has as much if not more importance to carrying out the Geron plans and strategy. These two new director appointments offer more proof of the trajectory we are on now.

http://ir.geron.com/news-releases/news- ... rd-members

Geron Appoints Two New Independent Board Members
Thu March 28, 2019 8:00 AM|GlobeNewswire|About: GERN

MENLO PARK, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (GERN) today announced the appointments of Dawn C. Bir and Elizabeth G. O’Farrell as independent members of its Board of Directors. In addition, Ms. Bir will serve as a member of the Board’s Nominating and Corporate Governance Committee, and Ms. O’Farrell will serve as a member of the Board’s Audit Committee.

“We enthusiastically welcome two accomplished biopharmaceutical executives to Geron’s Board, both of whom have deep experience with guiding the growth of companies from clinical to commercial stage,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer. “We believe their contributions will be invaluable as we advance our lead indication for imetelstat in lower risk MDS to Phase 3 clinical development and, in the future, begin preparations for the potential commercialization of imetelstat.”

Dawn C. Bir currently serves as the Chief Commercial Officer of Reata Pharmaceuticals, where she leads marketing, market access, sales and commercial operations. Prior to Reata, Ms. Bir served as Vice President of Sales with Pharmacyclics LLC, an AbbVie Company, where she built and led their first hematology national sales organization responsible for the launch of IMBRUVICA, a hematology-oncology product, in the United States and Puerto Rico. Ms. Bir has also held sales and marketing roles at SKY Pharmaceuticals Packaging, Inc. & Rx Pak, a unit within McKesson Corporation; Genentech, a member of the Roche Group; and Bristol-Myers Squibb Company. Ms. Bir holds a B.S. in Biology from Binghamton University in Binghamton, New York.

Elizabeth G. O’Farrell most recently served as Chief Procurement Officer and Head of Global Shared Services at Eli Lilly and Company. Throughout her 24-year career with Eli Lilly, she held several senior management positions in finance and corporate governance, including: Senior Vice President, Policy and Finance; Senior Vice President, Finance; Chief Financial Officer, Lilly USA; Chief Financial Officer, Lilly Canada; and General Auditor. Before joining Eli Lilly, Ms. O’Farrell was an accountant with Boise Cascade Office Products, and served as an auditor at Whipple & Company and Price Waterhouse. Ms. O’Farrell currently serves as a member of the board of directors of PDL BioPharma, Inc. and on the finance committee of the United Way of Brevard in Brevard County, Florida. Ms. O’Farrell holds a B.S. in accounting and an M.B.A. in management information systems, both from Indiana
University in Bloomington, Indiana.

huntingonthebluffs
Posts: 138
Joined: Wed Feb 24, 2016 12:00 am

Re: Geron Jobs and Personnel

Post by huntingonthebluffs » Thu Apr 18, 2019 4:54 pm

http://ir.geron.com/news-releases/news- ... pment-team

Geron Expands Senior Leadership of Its Development Team
MENLO PARK, Calif., April 18, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced an expansion of its development team’s senior leadership with the addition of three highly experienced professionals for key functional areas. Their oncology and drug development expertise will support Geron’s late-stage clinical development, including the planned opening of the Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes for screening and enrollment by mid-year 2019.

Vice President, Clinical Development – Faye Feller, M.D.

Prior to Geron, Faye Feller, M.D., was Senior Director, Clinical Leader on the myeloid program at Janssen Research and Development, LLC (Janssen). Prior to that role, Dr. Feller was a physician for multiple clinical trials of late-stage development assets at Janssen, including the IMbark Phase 2 clinical trial of imetelstat, and was responsible for protocol writing, regulatory interactions, medical monitoring, study results interpretation and preparation of abstracts and final study reports. Prior to Janssen, Dr. Feller was an attending physician and instructor in the leukemia department of Memorial Sloan Kettering Cancer Center in New York. Dr. Feller holds a B.A. from New York University and an M.D. from Mount Sinai School of Medicine. She completed her residency in internal medicine at Mount Sinai Hospital and her fellowship in medical oncology at Memorial Sloan Kettering Cancer Center.

As Vice President, Clinical Development, Dr. Feller will provide hematology-oncology medical expertise to the clinical science and operations teams in the execution and monitoring of clinical trials. In addition, she will also act as the primary medical point of contact between Geron and other medically qualified healthcare professionals, including clinical investigators, prescribers, medical professionals at payer organizations and regulatory authorities.

Vice President, Clinical Science and Operations – Laurie Sherman

Laurie Sherman has more than 20 years of experience in oncology drug development. Prior to joining Geron, Ms. Sherman was Senior Director, Compound Development Team Leader for non-small cell lung cancer (NSCLC) assets at Janssen, where she was responsible for multiple aspects of drug development, including: clinical strategy and execution; chemistry, manufacturing and controls (CMC); toxicology; and clinical pharmacokinetics. Preceding that role, Ms. Sherman held several senior positions in the late-stage team at Janssen, including Senior Director, Myeloid Portfolio Clinical Scientist Leader, where she led development strategy and overall clinical execution of myeloid clinical trials, including the imetelstat clinical trials, IMerge and IMbark. Prior to that role she was Senior Director, Lead Project Scientist on the ibrutinib mantle cell lymphoma program. Ms. Sherman has held various positions with increasing responsibilities across various drugs’ product life cycles, from initial Phase 1 clinical trials through late-stage development, including operational leadership for pivotal Phase 3 clinical trials and supporting regulatory filings of New Drug Applications and Marketing Authorization Applications at multiple pharmaceutical companies and organizations, including: GlaxoSmithKline plc; Pfizer Inc.; World Wide Clinical Trials, Inc.; and Affiliated Research Institute. Ms. Sherman has a B.S. in nursing from the University of Washington.

As Vice President, Clinical Science and Operations, Ms. Sherman will provide oversight and management of current and future clinical trials, as well as strategic and technical guidance to and management of the Company’s contract research organization and other vendors supporting clinical operation activities. She will also directly oversee and manage internal operations and personnel involved with clinical operations, clinical science, data management and medical writing functions.

Vice President, Quality – Denise Grippo

Denise Grippo has more than 18 years of experience in drug development. Prior to joining Geron, Ms. Grippo was Vice President, Quality at Iovance Biotherapeutics, Inc. where she was responsible for developing and executing quality policies and plans to ensure lifecycle management of their early- and late-stage clinical oncology portfolio. In addition to Iovance, Ms. Grippo has held various quality and compliance positions with increasing responsibility and scope at XenoPort, Inc.; Mylan Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Alvogen, Inc.; and Marietta Corporation. Ms. Grippo has an M.S. in clinical chemistry from University of Scranton and a B.A. in biology from Temple University.

As Vice President, Quality, Ms. Grippo will manage and direct the quality function at Geron, including establishing systems for quality assurance, quality control, quality systems, and overall clinical and manufacturing compliance. She will implement the Company’s quality vision and commitment internally and through interactions with partners, clinical research organizations, manufacturers and vendors.

jayfish101
Posts: 9
Joined: Tue Feb 23, 2016 5:48 pm

Re: Geron Jobs and Personnel

Post by jayfish101 » Thu Apr 18, 2019 5:10 pm

With these hires in addition to the recent hires, It appears to me that Geron is very serious and committed to developing MDS and probably other applications. Also, it appears there is much confidence in success with the level of people they are able to hire.

jayfish101
Posts: 9
Joined: Tue Feb 23, 2016 5:48 pm

Re: Geron Jobs and Personnel

Post by jayfish101 » Thu Apr 18, 2019 5:51 pm

With these hires in addition to the recent hires, It appears to me that Geron is very serious and committed to developing MDS and probably other applications. Also, it appears there is much confidence in success with the level of people they are able to hire.

jayfish101
Posts: 9
Joined: Tue Feb 23, 2016 5:48 pm

Re: Geron Jobs and Personnel

Post by jayfish101 » Thu Apr 18, 2019 6:18 pm

With these hires in addition to the recent hires, It appears to me that Geron is very serious and committed to developing MDS and probably other applications. Also, it appears there is much confidence in success with the level of people they are able to hire.

huntingonthebluffs
Posts: 138
Joined: Wed Feb 24, 2016 12:00 am

Re: Geron Jobs and Personnel

Post by huntingonthebluffs » Thu May 16, 2019 2:58 pm

Geron Continues to Build Senior Leadership of Its Development Team

MENLO PARK, Calif., May 16, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it is continuing to build the senior leadership of its development team with the addition of a Vice President, Biometrics, and a Vice President, Manufacturing. Their oncology and drug development expertise will support Geron’s late-stage clinical development, including the planned opening of the Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes for screening and enrollment by mid-year 2019.

Vice President, Biometrics – Ying Wan, M.D., Ph.D.

Ying Wan, M.D., Ph.D., has more than 17 years of biometrics experience within oncology drug development. Prior to Geron, Dr. Wan was Director and Functional Leader, Oncology Statistics, Statistics & Decision Sciences at Janssen Research and Development, LLC (Janssen). Dr. Wan’s tenure at Janssen spanned 12 years with increasing responsibility where she led the statistical strategy for imetelstat and most recently, multiple solid tumor programs, across all stages of development, including Balversa. In addition, she provided statistical support for Imbruvica, Zytiga, Procrit, and other compounds. As the statistical leader for the imetelstat program at Janssen, she led the statistical strategy for study design and provided statistical expertise throughout the execution of both the IMerge Phase 2/3 and the IMbark Phase 2 clinical trials. Prior to Janssen, Dr. Wan was a Biometrician, Senior Statistician at Merck & Co., Inc. Dr. Wan holds an M.D. from Shanghai Medical College of Fudan University in Shanghai, China; an M.S. in nutrition science and an M.S. in statistics from Penn State University; and a Ph.D. in statistics from Temple University.

As Vice President, Biometrics, Dr. Wan will manage and lead biostatistics and statistical programming. This includes leading statistical strategy for clinical development; supporting clinical projects by implementing innovative approaches in designs and analyses plans; and providing statistical and programming deliverables for clinical programs and submissions, while ensuring compliance with regulatory guidance, standards and processes.

Vice President, Manufacturing – Patrick Murphy

Patrick Murphy has an extensive leadership background in manufacturing and technical operations, and has guided over ten new investigational products from pilot to full-scale commercial production while ensuring both product and facility compliance with the regulations for the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). Prior to joining Geron, Mr. Murphy was Vice President, Technical Operations at Omniox, Inc., where he was directly responsible for global chemistry, manufacturing and control (CMC) activities, including quality assurance, quality control and manufacturing. Prior to that role, Mr. Murphy held manufacturing leadership positions with Anthera Pharmaceuticals, Inc.; Versartis, Inc.; Solstice Neurosciences, Inc.; Acologix, Inc.; and Abgenix, Inc. Mr. Murphy began his career in biotechnology manufacturing and technical operations with Genentech, Inc., a Roche Company, with increased roles and responsibility over his 19-year tenure. Mr. Murphy has a B.S. in chemistry from State University of New York, Binghamton.

As Vice President, Manufacturing, Mr. Murphy will lead the manufacturing function, which includes developing and executing a comprehensive global CMC strategy that encompasses manufacturing, process development, supply chain management, and technology transfer, across the product lifecycle of imetelstat from the planned Phase 3 clinical trial in lower risk myelodysplastic syndromes to potential new drug applications, and preparing for commercial manufacturing.

huntingonthebluffs
Posts: 138
Joined: Wed Feb 24, 2016 12:00 am

Re: Geron Jobs and Personnel

Post by huntingonthebluffs » Thu Jun 20, 2019 11:54 pm

Geron Appoints Vice President, Human Resources

MENLO PARK, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the appointment of Shannon Odam as Vice President, Human Resources. Ms. Odam joins other recently recruited senior leadership to further strengthen the organization as it expands its operations to support the planned opening of the Phase 3 portion of IMerge in lower risk myelodysplastic syndromes for screening and enrollment in the summer of 2019.

As Vice President, Human Resources, Ms. Odam will lead all aspects of a comprehensive human resources function, including oversight of policies and operations for leadership and talent management, training, organizational development, operational effectiveness and workforce planning. In addition, Ms. Odam will work in partnership with the executive team to evaluate, design and implement programs to create a cohesive, collaborative and high-performing culture to support the Company’s growth initiatives as Geron advances the imetelstat program into late-stage clinical development and potential commercialization.

Shannon Odam has more than 20 years of experience leading human capital strategy development and execution in dynamic cultures that lead to accelerating organizational performance. Prior to Geron, Ms. Odam was Vice President, Human Resources at BioElectron Technology and a member of the executive team, where she led human resources planning and operations to establish strategic alignment. Prior to that, Ms. Odam was Market Diversity Leader at PricewaterhouseCoopers LLP (PwC), Silicon Valley. Ms. Odam’s tenure at PwC spanned 10 years with increasing responsibility where she focused on leading the Silicon Valley practice through a rapidly changing business environment as well as developing, retaining and advancing employees through implemented programs. She also provided executive coaching at all levels of the organization. Ms. Odam holds a B.S. in criminology from California State University, Fresno, and an M.S. in human resources and organizational development from University of San Francisco. In addition, Ms. Odam received a certification in executive coaching from The Hudson Institute in Santa Barbara, California.
Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

In connection with the commencement of employment, the Company has granted non-statutory stock options to purchase an aggregate of 478,400 shares of Geron common stock to Ms. Odam and two other new employees. The stock options were granted on June 19, 2019 at an exercise price of $1.59 per share, which is equal to the closing price of Geron common stock on the date of grant. Each stock option granted has a 10-year term and vests over four years, with 12.5% of the shares underlying the option vesting on the six-month anniversary of commencement of employment and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates. Each stock option was granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and is subject to the terms and conditions of a stock option agreement covering the grant and Geron’s 2018 Inducement Award Plan, which was adopted December 14, 2018 and provides for the granting of stock options to new employees.

http://ir.geron.com/news-releases/news- ... -resources

Post Reply